Overall verdict
Sell
2.4/10
1-year performance
-11.54%
Score breakdown
Down 11.5% over 1 year, 8% of the 52-week range.
Strongest: Growth 7.9/10. Weakest: Shareholder return 0.0/10.
AbClon Inc. engages in the research and development of antibody drugs in South Korea and Sweden. The company's products in pipeline include NEST platform technology products for breast and gastric cancers; AffiMab platform technology products for colon cancer and autoimmune diseases; and CAR-T platform technology products for hematologic and ovarian cancers. AbClon Inc. was founded in 2010 and is based in Seoul, South Korea.
Sector
Health Care
Industry
Biotechnology
Primary listing
Krx
South Korea
CEO
Dou Xian Jin
Founded
2010
Employees
66
Revenue / employee
71.4M KRW
Next earnings
—
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
95800.00 KRW
52-week low
15800.00 KRW
1-year performance
-11.54%
Declining
Year-to-date performance
-49.77%
Declining
Drawdown
-77.19%
Major drawdown
Position in the 52-week range
8% of range
Gross margin -3.2%, the company loses 328.3% of its revenue, ROIC -40.6%, ROE -57.8%.
Net margin
-328.26%
Negative
Sector -204.15%|S&P 13.40%
Gross margin
-3.19%
Negative
Return on equity (ROE)
-57.81%
Negative
Sector -57.88%|S&P 17.06%
Return on invested capital (ROIC)
-40.61%
Negative
Free cash flow margin (FCF)
-260.88%
Negative
Margin stability
217.1 pts
Very uneven
Growth
7.9/10Revenue up 51.4% over 1 year, 11.2% a year over 5.
Revenue (trailing 12 months)
4.9Md KRW
Revenue growth (1y)
51.44%
Hyper-growth
Revenue growth (3y)
38.39%
Solid
EPS growth (1y)
—
EPS CAGR (5y)
—
EPS revisions (3 months)
—
Valuation
0.0/10The company loses money, so no valuation multiple can be read: a negative P/E is not a discount.
P/E (TTM)
—
N/A (loss)
Sector 11.8x|S&P 23.6x
Forward P/E (adjusted)
—
EV / EBITDA
—
N/A (loss)
Sector 15.0x|S&P 15.5x
PEG
—
Sector 1.50|S&P 0.91
Market cap
448Md KRW
Financial strength
6.6/10Cash covers 111.6% of the debt, net debt/EBITDA 1.7x.
Net debt / EBITDA
1.7x
Tight
Gearing (net debt / equity)
-13.54%
Net cash
Cash
33.8Md KRW
Cash / market cap
7.55%
Tight
Cash / total debt
111.59%
Net cash
Interest coverage
-55.6x
Stretched
Net debt
-3.5Md KRW
Equity
26.0Md KRW
Closed daily candles, 2 years
Last close on November 11, 2026: 22,600.00 KRW
- MM2020,393.00
- MM5021,627.20
- MM20039,155.55
- RSI 1456.1
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
-6.50%
200-day average slope, 3 months
-8.28%
50-day average slope, 1 month
-11.94%
Price structure
higher-low
Bullish RSI divergence
No
20-day volatility
7.31 % per day
Volatility change
+18.53%
Same sub-industry: 772 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | LRMR | 5.6 | N/A | 284M USD | Not meaningful (loss) | — | — | -135.7 % | 0.8x | -55.0 % | -21.3 % | ||
| 2 | FYB | 4.8 | 3.2 | 290M USD | Not meaningful (loss) | -41.0 % | -36.2 % | -6.2 % | -4.2x | -2.2 % | -30.3 % | ||
| 3 | ALERS | 4.3 | 4.4 | 287M USD | 36.9x | 4.2 % | 9.1 % | 3.7 % | -0.1x | 2.0 % | 7.1 % | ||
| 4 | NWBO | 3.5 | 4.0 | 290M USD | Not meaningful (loss) | -1736.4 % | 535.4 % | 275.6 % | -1.3x | -17.2 % | -32.6 % | ||
| 5 | 688426 | 2.9 | 3.2 | 299M USD | Not meaningful (loss) | -35.4 % | 24.1 % | -6.0 % | — | -0.5 % | -35.6 % | ||
| 6 | SABS | 2.9 | 0.9 | 280M USD | Not meaningful (loss) | -6088.9 % | -100.0 % | -34.5 % | 1.2x | -21.0 % | -1.3 % | ||
| 7 | LCTX | 2.7 | 1.5 | 281M USD | Not meaningful (loss) | -246.6 % | -61.3 % | -57.7 % | 1.9x | -8.7 % | -43.3 % | ||
| 8 | A174900 | 2.4 | 2.6 | 335M USD | Not meaningful (loss) | -328.3 % | 51.4 % | -40.6 % | 1.7x | -2.9 % | -11.5 % | ||
| 9 | CRNA | 1.8 | 0.4 | 298M USD | Not meaningful (loss) | — | — | -25.6 % | 8.3x | -1.8 % | 900.5 % |
